Why Small Molecule Experience Doesn't Bridge the Gap to Biologics Hiring at CDMOs

The $15.2 billion invested in cell and gene therapy in 2025 alone tells you something about the pace at which CDMOs are being asked to build capability. What it doesn't tell you is how many of those programmes will stall not because of equipment or capacity, but because the scientific talent brought in to deliver them wasn't built for the work.

This is a biologics hiring problem that most CDMOs haven't named clearly yet. The assumption running underneath a lot of expansion decisions is that experienced manufacturing scientists, particularly those from small molecule backgrounds, can be upskilled or bridged into biologics and CGT roles within a reasonable timeframe. In some cases that's partially true. As a general hiring strategy, it's costing programmes months they don't have.

‍

The technical distance is larger than the org chart suggests

Small molecule and biologics manufacturing share a vocabulary, and that shared vocabulary disguises how different the underlying science is. A scientist who has spent years in solid dosage form development has genuine, hard-won expertise, but the core competencies that expertise rests on, synthetic chemistry, physical characterisation, stability under heat and humidity, don't map cleanly onto the challenges of working with living systems.

Biologics manufacturing is process-sensitive in a fundamentally different way. The product is the process, as the field has long acknowledged, and that means understanding how cell culture conditions, upstream variability, and downstream purification interact to determine product quality. A small molecule scientist encountering this for the first time isn't starting from zero, but they're not starting from the middle either. The learning curve is steeper and longer than most hiring timelines account for.

CGT compounds this further. Working with viral vectors, autologous cell therapies, or gene-edited constructs requires familiarity with a methods landscape that simply doesn't exist in conventional pharmaceutical manufacturing. Aseptic technique at this scale, the regulatory expectations around comparability, the cold chain and logistics complexity around autologous products: these are learned through direct exposure, not through adjacent experience.

‍

Where the gap actually surfaces

The mismatch rarely reveals itself in interview. Scientists from strong small molecule backgrounds are technically confident, they speak the language of GMP fluently, and they often have the process rigour that biologics CMOs genuinely need. The gap doesn't show up in competency frameworks or panel discussions. It shows up at tech transfer.

Tech transfer is where a biologics programme gets handed from development to manufacturing, and it's where the depth of scientific ownership becomes visible. A scientist who hasn't spent time developing or troubleshooting biologic-specific analytical methods, working through the uncertainty of cell line stability, or navigating the comparability studies that regulators expect before and after a process change will encounter decisions they're not equipped to make independently. The programme doesn't fail dramatically. It slows. Queries go back to the client. Timelines slip. Confidence erodes on both sides.

The analytical science dimension deserves specific attention here. Many job specifications describe QC experience as equivalent to, or a pathway into, analytical development in biologics. The methods lifecycle in biologics analytical development is a distinct skill set. Developing and qualifying new characterisation methods for a novel biologic, understanding the criticality of certain quality attributes, or managing the analytical strategy through regulatory submission is not what QC scientists do in a small molecule environment. Conflating these two profiles at the point of hiring creates a gap that's invisible until it isn't.

‍

What the right profile actually looks like

Most job specifications for biologics and CGT roles at CDMOs are written to describe the role's context rather than the technical ownership it requires. They list modalities, therapeutic areas, and equipment. They don't always articulate the decision-making latitude the scientist will need, or the specific process knowledge they'll be expected to bring from day one rather than develop on the job.

A strong biologics CMC scientist brings process characterisation experience, meaning they've participated in or led the experimental work that links process parameters to product quality attributes. A strong CGT manufacturing scientist has worked within the specific modality, whether lentiviral, AAR, or cell therapy, at a stage comparable to where the CDMO's programme is. Proximity to the science matters here more than seniority.

The assessment process needs to test technical ownership, not just technical exposure. The difference is between a candidate who has worked on a biologics programme and one who has made independent scientific judgements within it. Structured technical interviews, specific scenario questions around troubleshooting or process deviation management, and a clear articulation in the brief of what the scientist will be responsible for on day sixty rather than day three hundred will screen for this far more effectively than credential checking.

‍

The retraining calculation CDMOs are getting wrong

There's a version of this conversation where internal development is the answer. Invest in training existing scientists, build the biologics capability over time, preserve headcount continuity. For some organisations with long enough runways, that's a reasonable strategy. For CDMOs with signed client contracts and programme start dates, it usually isn't.

The economics of retraining a scientist from small molecule into biologics manufacturing, accounting for time away from productive output, the cost of errors during the learning period, and the management resource required to support the transition, frequently exceeds the cost of hiring someone with the right modality background from the start. The maths changes when the retraining happens ahead of programme need rather than in response to it, but most CDMOs making rapid modality expansions don't have that luxury.

The CDMO sector is operating in a market that rewards speed. Clients choosing a CDMO partner for a biologics or CGT programme are evaluating technical credibility alongside capacity. Hiring scientists who need eighteen months to develop the capability the client assumes is already in place isn't just an internal people problem. It's a commercial risk.

‍

One question every brief should answer first

Before a biologics or CGT hiring brief goes to market, there's a question worth putting in front of the hiring team: what will this scientist be expected to own technically within their first six months, and does our candidate pool have people who can do that without significant hand-holding?

If the honest answer is that the role requires expertise the organisation doesn't yet have internally, the brief needs to reflect that, in the seniority level, the specificity of the technical requirements, and the assessment approach. A job specification written to describe a small molecule role with biologics terminology added is not a biologics hiring brief. It's an optimistic reframe of a capability gap, and it will attract candidates who fit the language rather than the work.

The CDMOs expanding fastest into biologics and cell and gene therapy right now are the ones treating modality-specific hiring as a technical discipline in its own right. The ones moving slower than they expected are often still solving it with general scientific recruitment and hoping the gap closes on the job.